(Upd:) Ocular Therapeutix OCUL stock trades 23% lower at $6.81 despite positive results from its pivotal Phase 3 SOL-1 trial in wet age-related macular degeneration (AMD).
Safety findings were favorable, with no treatment-related ocular or systemic serious adverse effects observed. Researchers noted that AXPAXLI’s performance suggests the potential for a reduced treatment burden, with some patients possibly requiring only annual dosing.
Executives and trial researchers described the trial results as a historic advance in retinal care, positioning AXPAXLI as the first therapy to achieve superiority in wet AMD under FDA’s stringent evidentiary standards.
—————————
Ocular Therapeutix OCUL stock trades 30% higher at $11.56 in premarket trading as traders and investors are highly optimistic ahead of the company’s scheduled 8:00 a.m. ET webcast to announce topline results from the SOL-1 Phase 3 superiority trial for AXPAXLI (OTX-TKI) in treating wet age-related macular degeneration (wet AMD).
Positive test results would support an expedited New Drug Application (NDA) submission by mid-2026, potentially making it the first long-acting treatment of its kind on the health market.
Meanwhile, rumors have resurfaced about the French pharma giant Sanofi is preparing a revised bid for Ocular Therapeutix. Sanofi previously had an offer of $16 per share rejected when the stock was trading around $10.35.
Nikolas has been involved in the finance industry for over fifteen years spanning across Europe and USA with a depth of knowledge and experience within many aspects of the financial markets. Nikolas gained several years experience with some of the Europe’s leading Brokers, as equity analyst, and trader managing accounts for both Private and Corporate Investors. He enjoys both the fundamental and technical aspects of trading focusing on stock markets and all FX majors. Currently, Nikolas provides analysis and comments to online financial publications. Educational background in Economics (BSc), and Finance (MSc).